JAMA review of ILD; that affects 650,000 in USA, leading to 25,000-30,000 deaths/YR. Types reviewed. Key Symptoms: dyspnea and cough, w/ chest CT being diagnostic tool. Antifibrotic & immunomodulatory may slow disease progression. https://t.co/tE7kHgUE02 https://t.co/V7Htoct3VP

• Interstitial Lung Disease

Is Colchicine Rx a problem? Retrospective study of UK Clinical Practice registry, 13945 gout initiated allopurinol with colchicine (64yrs; 78% male). 26% on 1+ meds interacting w/ colchicine. Diarrhea & MI more freq w/ comorbidities & more severe CKD https://t.co/ZkhpzaTjjI https://t.co/e3BO813b30

• Prognostic factors for colchicine prophylaxis-related adverse events when initi…

'Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases’ - a 6 center consortium will study if JAKi (filgotinib) is effective and safe in 3 rare disorders -- Behcets, inflammatory myositis & IgG4 related disease. https://t.co/UyZM4VNSY2 https://t.co/D2D1tdygS4

• Existing drugs studied in patients with rare immune diseases

Articular Findings Sarcoidosis: - Acute arthritis: Lg Jt Oligoarthritis; Loffgrens syndrome (hilar LN, arthritis, E. nodosum) - Acute > Chronic arthritis - Chronic arthritis: tenosynovitis, oligo- &polyarthritis, dactylitis, erosions or Jaccouds arthritis

Hyperpigmentation from Hydroxychloroquine. From 316 HCQ pts, 26% got hyperpigmentation; delayed onset of 12 mos (6–30mos) after median cum. dose of 108 g. Seen on face (602%), Legs (36%) & hands (20%). Daily sun exposure decrease in the incidence (P=0.02) https://t.co/6B6Z0suXB4

• Hydroxychloroquine-induced pigmentation in rheumatic diseases: prevalence, clin…

Predicting CKD Outcomes in Lupus Nephritis An observational cohort study suggests that proteinuria levels in lupus nephritis (LN) patients did not predict their histologic class. https://t.co/SCsuYuXgw4 https://t.co/bHB9ggf20H

• Predicting CKD Outcomes in Lupus Nephritis | RheumNow

1/3 of lupus nephritis patient classified as ""complete responders"" continued to accrue progressive renal damage despite resolution of proteinuria over 1 year. Dr. @andreafava reviews GFR trajectories after renal bx at #RNL2024 @RheumNow https://t.co/mqwhfIFQsL

• https://buff.ly/3xSICHa

#RNL2024 @DrDavidKarp Incomplete lupus is heterogeneous term ""Stage 2"" pre-classification stage as ILE/UCTD Stage 1: non-specific antibodies, dysregulation 2: incomplete features 3: classified, multi-system disease 4: irreversible tissue damage https://t.co/lmorwojG49

• https://buff.ly/4aNqFID

Urine proteomics in lupus nephritis IL-16 and CD163 are urinary biomarkers most correlated w/ histologic activity Myeloid & degranulation sign ass w histo activity -> PR3+cells abundant in LN @andreafava #RNL2024 @RheumNow https://t.co/YpoMiupOlQ

• https://buff.ly/4aWvwra

Venous thromboembolic event Risk study in 1854 SLE pts vs controls (12,107) from 1985–2015 in W Australia. VTE affected 12.8% SLE pts; 6 fold higher than controls (RR 6.6). Risk factors: aPL(aHR 4.24), serositis (2.7), nephritis (1.75), low Plts (1.65) https://t.co/KNInhNkjmQ https://t.co/jT3cTemxMD

• Long-term incidence, risk factors and complications for venous thromboembolism …

Our final TNR for the month of April will take place on 4/30 at 6:30pm ET. Mastering SLE Rethinking Pre-Clinical Disease in Lupus - David Karp, MD Biology and Rx of Lupus Flares - Michelle Kahlenberg, MD Current/Future Biomarkers in SLE - Andrea Fava, MD https://t.co/IoRDAaAJbo https://t.co/C7HpKvehXX

• RheumNow.com

Prospective look at 25 280 older adults (mean 74yrs) w/ incident fracture, shows impact of multimorbidity by Charlson Comorbid Index (CCI). If CCI =2-3, Incr risk of subseq Fx (16-25%) & death (HR ~2); If CCI=4+, Fx Risk ^33-48%, death HR~4. https://t.co/6wnhFNiSXH https://t.co/Xy2y0ANDRd

• Health Perceptions, Multimorbidity, and New Fractures and Mortality After a Fra…

Prevalence of MSK presentations in practice = 21.1%, based on UK practice cohort. Most common: pain in LS spine (18%) & knee (17%). Re-presentations of existing Dx made up 74% all MSK consultations. Steroid injx given to 1/3 of knee consults https://t.co/nTioq1lCEB https://t.co/ecm8Kxz2cu

• The prevalence of musculoskeletal presentations in general practice: an epidemi…